Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by Atle Fund Management AB

Atle Fund Management AB lessened its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 12.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 93,605 shares of the company’s stock after selling 13,307 shares during the period. Mirum Pharmaceuticals comprises approximately 2.7% of Atle Fund Management AB’s holdings, making the stock its 16th biggest holding. Atle Fund Management AB owned about 0.19% of Mirum Pharmaceuticals worth $6,862,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. CWM LLC increased its holdings in Mirum Pharmaceuticals by 30.8% in the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after purchasing an additional 161 shares in the last quarter. Comerica Bank boosted its position in shares of Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after buying an additional 278 shares during the period. Osaic Holdings Inc. grew its stake in shares of Mirum Pharmaceuticals by 46.5% in the second quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock valued at $56,000 after buying an additional 351 shares in the last quarter. Hollencrest Capital Management acquired a new stake in shares of Mirum Pharmaceuticals in the third quarter valued at about $138,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Mirum Pharmaceuticals by 14.9% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,914 shares of the company’s stock valued at $97,000 after buying an additional 248 shares during the period.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on MIRM shares. JMP Securities set a $95.00 price target on Mirum Pharmaceuticals in a report on Wednesday, November 5th. Leerink Partners set a $100.00 target price on shares of Mirum Pharmaceuticals in a research report on Wednesday, December 10th. Citizens Jmp upped their target price on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the company a “market outperform” rating in a research note on Friday, December 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $130.00 price target on shares of Mirum Pharmaceuticals in a report on Monday, December 8th. Finally, TD Cowen reiterated a “buy” rating on shares of Mirum Pharmaceuticals in a report on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Mirum Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $107.25.

Insiders Place Their Bets

In other news, Director Patrick J. Heron purchased 131,425 shares of the stock in a transaction dated Friday, January 23rd. The stock was acquired at an average cost of $68.48 per share, for a total transaction of $8,999,984.00. Following the acquisition, the director owned 459,010 shares of the company’s stock, valued at $31,433,004.80. The trade was a 40.12% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Peter Radovich sold 3,143 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $96.19, for a total value of $302,325.17. Following the sale, the chief operating officer directly owned 23,286 shares in the company, valued at approximately $2,239,880.34. This represents a 11.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 32,429 shares of company stock valued at $3,039,396. 14.36% of the stock is owned by company insiders.

Mirum Pharmaceuticals Stock Up 0.3%

Shares of NASDAQ:MIRM opened at $103.22 on Friday. The firm has a market cap of $5.30 billion, a PE ratio of -120.02 and a beta of 0.48. The company has a fifty day simple moving average of $80.29 and a 200 day simple moving average of $72.45. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. Mirum Pharmaceuticals, Inc. has a 12-month low of $36.88 and a 12-month high of $103.81.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.15. The company had revenue of $133.01 million during the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The firm’s revenue for the quarter was up 47.1% compared to the same quarter last year. During the same period last year, the business earned ($0.30) EPS. On average, equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.